Exenatide

Overview

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. WPF organizes its research by formulation, type 2 diabetes outcomes, comparative studies, safety and tolerability, and other investigated questions. Formulation and dosing schedules differ across studies, so results from one preparation or population should not automatically be generalized to another.

Evidence quality

WPF already displays a deduplicated Exenatide research atlas with ranked source records and a separate set of directly attributable studies. The featured set includes a cardiovascular outcomes trial in type 2 diabetes (PMID 28910237), a randomized comparison with semaglutide extended-release exenatide (PMID 29246950), and a trial in alcohol use disorder (PMID 36066977). These address different questions; the latter must not be described as establishing treatment benefit from the brief source excerpt alone. Proposed ranks and tiers are discovery aids, not approved conclusions.

Safety concerns

The current Directory entry has not promoted its screening inventory into a fully source-linked editorial synthesis. A paper may concern a different population, formulation, comparator, or endpoint, and a review does not replace examination of the underlying studies. The absence of published citations in this Directory lane reflects its workflow state, not absence of research.

Citations as of this version

• Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
• Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
• Exenatide.
• Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
• Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.